UNSPSC 51332821: Periciazine

This classification denotes an antipsychotic agent with the molecular formula C21H23N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3405M6FD73, chemically known as 4-piperidinol, 1-(3-(2-cyano-10-phenothiazinyl)propyl)- but generally known as periciazine, which bears US NIH Compound Identifier 4747. European Medicines Agency schedules Periciazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09727MIG. The term PERICIAZINE is an International Non-Proprietary Name.

UNSPSC 51332821 Periciazine is a Commodity code that represents a specific antipsychotic medication, but recent state and local solicitations tagged with this code show substantial activity in broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals and over-the-counter products. The mismatch between the code's narrow pharmaceutical name and the wide-ranging health-related procurement it nominally covers reflects how state and local governments use UNSPSC classifications to tag health supply and pharmacy initiatives across multiple product categories and therapeutic areas. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that coordinate procurement for state facilities and participating localities. Recent work spans emergency-response pharmaceuticals, prescription fulfillment innovation, and routine generic-drug supply contracts.

Recent activity appears across three distinct procurement models. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding with a July 26, 2023 response deadline and quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and market availability required by May 15, 2026, distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson). Geographic activity spans Florida, Texas, Minnesota, and participating cooperative-purchasing states including Oregon. The MMCAP solicitation emphasizes current Good Manufacturing Practice certification, Drug Supply Chain Security Act compliance, and pricing competitiveness weighted at 75 percent of award criteria.